Nice — below is a compact, evidence-backed market reference for the Atherosclerosis Drugs Market you can use immediately:
(A) a short list of key companies with “values” (country + core product / role), and (B) concise, sourced notes for each section you requested. I cite the most important sources so you can follow up.

This versatile research report is presenting crucial details on market relevant information, harping on ample minute details encompassing a multi-dimensional market that collectively maneuver growth in the global Atherosclerosis Drugs market.

This holistic report presented by the report is also determined to cater to all the market specific information and a take on business analysis and key growth steering best industry practices that optimize million-dollar opportunities amidst staggering competition in Atherosclerosis Drugs market.

Read complete report at: https://www.thebrainyinsights.com/report/atherosclerosis-drugs-market-12998

A — Key companies (company · country · core value / specialty)

1. Amgen · USA — PCSK9 monoclonal antibody Repatha® (high-efficacy LDL lowering; strong commercial footprint).

2. Regeneron / Sanofi · USA / France — PCSK9 mAb Praluent® (competes with Repatha; large clinical/commercial programs). 

3. Novartis · Switzerland — Leqvio® (inclisiran) siRNA LDL-C lowering (twice-yearly dosing; rapidly growing sales).

4. Esperion Therapeutics · USA — oral bempedoic acid (NEXLETOL / NEXLIZET) — an oral non-statin LDL-lowering option, outcome data and label expansion activity. 

5. Merck · USA — oral PCSK9/novel small-molecule candidates in development (high potential to disrupt injectables if approved). 

6. Pfizer · USA — historically large player in lipid management (statins & broad CV portfolio) and active in combinations and CV pipelines.

7. Other important players / enablers — big pharmas (AstraZeneca, Roche/Genentech), specialty biotechs (gene editing companies, small-molecule PCSK9 developers), and generics/biosimilar makers who influence pricing & access.

B — Market snapshot (evidence-backed)

Market size & recent estimates (why numbers vary)

• Different market reports use different definitions (atherosclerosis drugs overall vs. lipid-lowering subset). Examples: Mordor Intelligence estimates ~USD 34.4B (2025) with mid-single digit CAGR to 2030; Precedence Research reports ~USD 17.0B (2024) and projects ~3.6% CAGR; PCSK9-specific studies value that submarket at ~USD 2.4–2.9B (2024–2025) with high projected CAGR. Report-to-report variation reflects scope (all atherosclerosis therapies vs. lipid-lowering only).

Recent developments

• Inclisiran (Leqvio) has seen rapid uptake and revenue growth (Novartis reporting strong year-on-year sales expansion; analysts project multi-billion peak sales).

• PCSK9 injectables (Repatha, Praluent) remain important commercial drivers — aggregated 2024 revenues for approved PCSK9 products were substantial (Repatha & Praluent + Leqvio contributing materially).

• New oral PCSK9 entrants (e.g., Merck’s oral candidate) and small-molecule approaches have advanced in trials — these could materially change access and adoption if approved. 

• Clinical/market-access news (legal/regulatory actions, payer behavior) continue to shape uptake — e.g., competition/antitrust litigation has affected the competitive landscape. 

Drivers

• Rising prevalence of cardiovascular disease (CVD), aging populations, diabetes & obesity increasing atherosclerosis burden.

• Large unmet need: many high-risk patients do not reach guideline LDL-C targets on statins alone → drives demand for add-on therapies (PCSK9, siRNA, bempedoic acid). 

• Clinical guideline updates and outcomes evidence that emphasize lower LDL-C targets encourage use of potent therapies (and justify payer coverage in many regions).

Restraints

• High cost / payer restrictions for injectables (PCSK9 mAbs historically faced narrow coverage, though access has eased recently).

• Competition from low-cost generics (statins) for first-line therapy and cost-effectiveness scrutiny for newer agents.

• Safety, long-term outcome & adherence questions (especially for novel modalities) can slow broader use.

Regional segmentation analysis

• North America: largest & earliest commercial adoption (high per-capita spend, aggressive guideline implementation).

• Europe: strong uptake in targeted high-risk populations; price negotiations and national formularies shape adoption.

• APAC (China, Japan, India): fast growth potential — rising CVD burden, growing market access programs, and local pricing dynamics. (Report estimates show APAC as a high-growth region).

Emerging trends

• Shift toward less-frequent dosing biologics/siRNA (inclisiran) and interest in oral PCSK9 inhibitors — these improve adherence and broaden addressable patients. 

• Combination therapies (statin + non-statin fixed doses) and tailored therapy for statin-intolerant patients (e.g., bempedoic acid).

• Gene-editing & one-time therapies (early stage) targeting long-term LDL-lowering — large potential upside but early clinical risk. 

Top use cases

1. Secondary prevention in ASCVD (patients with prior MI/stroke) — intensive LDL lowering to reduce recurrent events.

2. Heterozygous & homozygous familial hypercholesterolemia (HeFH / HoFH) — necessitates high-potency agents (PCSK9, inclisiran, sometimes LDL apheresis).

3. Statin-intolerant patients — oral nonstatin agents and add-ons (bempedoic acid, PCSK9 inhibitors).

4. Primary prevention in very high-risk patients (diabetes, chronic kidney disease, familial risk). 

Major challenges

• Payer economics & cost-effectiveness: demonstrating value vs. well-priced generics is essential to widen use.

• Patient identification & adherence: many eligible patients remain untreated or undertreated (care gaps).

• Long-term outcomes & safety evidence for newer modalities and one-time/gene therapies. 

Attractive opportunities

• Oral PCSK9 drugs (if approved) — big market unlock through easier administration and potentially lower cost.

• Expanding use of inclisiran (twice-yearly siRNA) into earlier lines of therapy and broader patient groups — strong revenue upside already visible. 

• Emerging markets & primary-care deployment — programs to identify & treat high-risk patients in APAC/LatAm.

• Combination products & fixed-dose regimens targeting adherence and uptake.

Key factors of market expansion

1. Guideline & reimbursement changes encouraging earlier, more aggressive LDL lowering.

2. Commercial adoption of convenient modalities (twice-yearly inclisiran, oral PCSK9 if approved) that improve adherence and broaden usage.

3. Positive outcome trials & real-world evidence showing event reductions vs. cost — drives payer coverage and physician prescribing.

Most load-bearing citations (pick any to open)

• Market sizing examples (different methodologies): Mordor Intelligence (USD 34.4B estimate for 2025).

• PCSK9 market and revenue snapshot (2024 PCSK9 product revenues; Repatha/Praluent/Leqvio aggregate contribution).

• Novartis Leqvio (inclisiran) rapid sales growth & forecasts (Novartis sales disclosures / analyst commentary). 

• Esperion (bempedoic acid) outcome data and recent company updates (CLEAR Outcomes / earnings releases).

• Merck oral PCSK9 candidate coverage (news on promising Phase results and potential market disruption).